Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02848248 (Clincal Trial/ SGN-CD123A)

Study Title
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia (NCT02848248)

Trial Description
The study will examine the safety profile of SGN-CD123A. The study will test increasing doses of SGN-CD123A given every 3 weeks to patients This trial is sponsored by Seattle Genetics, Inc. ®

Study Data

  • Condition: Acute Myeloid Leukemia
  • Interventions:
    • Drugs used in this trial
      • SGN-CD123A
  • Phase: I
  • Enrollment: 106
  • Start: August 2016
  • Estimated Completion: June 2019
  • Last verified: September 2016
  • Last Updated: September 2016

Study Schematic

screen-shot-2016-10-10-at-9-09-21-pm

Click here to Return to Drug map


Last Editorial review: October 10, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar